Kaur 2011.

Study characteristics
Methods	Design: cross‐over Duration: 6 weeks Assessment: baseline and post‐intervention Country: India
Participants	Pain condition: diabetic peripheral neuropathy Population: adults with type 2 diabetes and diabetic peripheral neuropathy Minimum pain intensity: ≥ 50 on 0‐100 VAS Inclusion criteria Aged 18‐75 diabetic peripheral neuropathy for at least 1 month ≥ 50 on 0‐100 pain intensity VAS Exclusion criteria Clinically significant physical or mental health comorbidities Total participants randomised: 65 Age in years (median, IQR): 52.5 (48.2–62) Gender: 31/65 were female Pain duration in years (median IQR): 8 (6–36)
Interventions	Amitriptyline 10‐50 mg TCA Flexible titration with fixed doses: started at 10 mg, with optional titration every 2 weeks to 25 mg, and then 50 mg Duloxetine 20‐60 mg SNRI Flexible titration with fixed doses: started at 20 mg, with optional titration every 2 weeks to 40 mg, and then 60 mg
Outcomes	Moderate pain relief Substantial pain relief
Missing data methods	Unclear regarding methods
Funding source	NR
Conflicts of interest	No potential conflicts of interest relevant to this study were reported
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomised using computer‐generated randomisation of blocks of 4
Allocation concealment (selection bias)	Low risk	The drug packets were administered to patients serially according to the patient’s reporting sequence.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Says double‐blind but no information given regarding procedure e.g. appearance of tablets
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Self‐reported outcomes by participants but not enough information given regarding blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear reporting of withdrawals and analysis. State ITT analysis but only including those 58 who completed the study Attrition Total: 7/65 (10.8%) Attrition per arm NR
Selective reporting (reporting bias)	Unclear risk	No protocol or trial registration found
Other bias	Low risk	No other sources of bias were identified.